Neurology Department, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, People's Republic of China.
Department of Hepatology, The First Hospital of Jilin University, Changchun, People's Republic of China.
Emerg Microbes Infect. 2020 Dec;9(1):1695-1701. doi: 10.1080/22221751.2020.1791736.
The COVID-19 pandemic has caused a global public health crisis. There is a pressing need for evidence-based interventions to address the devastating clinical and public health effects of the COVID-19 pandemic. The Chinese scientists supported by private and government resources have adopted extensive efforts to identify effective drugs against the virus. To date, a large number of clinical trials addressing various aspects of COVID19 have been registered in the Chinese Clinical Trial Registry (ChiCTR), including more than 200 interventional studies. Under such an urgent circumstance, the scope and quality of these clinical studies vary significantly. Hence, this review aims to make a comprehensive analysis on the profiles of COVID-19 clinical trials registered in the ChiCTR, including a wide range of characteristics. Our findings will provide a useful summary on these clinical studies since most of these studies will encounter major challenges from the design to completion. It will be a long road for the outcomes of these studies to be published and international collaboration will help the ultimate goals of developing new vaccines and anti-viral drugs.
新冠疫情引发了全球公共卫生危机。目前迫切需要采取循证干预措施，以应对新冠疫情给临床和公共卫生带来的破坏性影响。中国科学家在私人和政府资源的支持下，已经做出了广泛努力，以寻找针对该病毒的有效药物。迄今为止，中国临床试验注册中心（ChiCTR）已注册了大量针对新冠疫情各个方面的临床试验，其中包括 200 多项干预性研究。在这种紧急情况下，这些临床研究的范围和质量差异很大。因此，本综述旨在对 ChiCTR 注册的新冠疫情临床试验的概况进行全面分析，包括广泛的特征。我们的研究结果将为这些临床研究提供有用的总结，因为这些研究中的大多数都将在设计到完成过程中遇到重大挑战。这些研究的结果要公布还需要很长的时间，而国际合作将有助于实现开发新疫苗和抗病毒药物的最终目标。
